Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) Stock Rated “Hold” by Wall Street Brokerages

Shares of Silence Therapeutics PLC Sponsored ADR (NASDAQ:SLN) have been assigned a consensus rating of “Hold” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and two have issued a buy rating on the company. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $24.00.

SLN has been the topic of a number of research reports. Weiss Ratings restated a “sell (d-)” rating on shares of Silence Therapeutics in a research note on Thursday, October 15th. Morgan Stanley lifted their price objective on Silence Therapeutics from $25.00 to $32.00 and gave the stock an “overweight” rating in a report on Tuesday, August 11th. Chardan Capital cut Silence Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, October 21st. William Blair downgraded Silence Therapeutics from an “outperform” rating to a “hold” rating in a report on Monday, October 19th. Finally, Jefferies Financial Group cut Silence Therapeutics from a “buy” rating to a “hold” rating and set a $20.00 target price on the stock. in a research report on Monday, October 19th.

Silence Therapeutics Stock Up 0.6%

Shares of Silence Therapeutics stock opened at $19.78 on Tuesday. The company has a market cap of $1.19 billion, a price-to-earnings ratio of -15.45 and a beta of 1.45. The company’s 50 day moving average is $13.00 and its 200 day moving average is $8.76. Silence Therapeutics has a twelve month low of $4.19 and a twelve month high of $19.87.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Monday, August 10th. The company reported ($0.26) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.12). Silence Therapeutics had a negative return on equity of 106.94% and a negative net margin of 8,943.86%. Sell-side analysts expect that Silence Therapeutics will post -0.82 EPS for the current fiscal year.

Hedge Funds Weigh In On Silence Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. ADAR1 Capital Management LLC raised its position in Silence Therapeutics by 628.2% in the first quarter. ADAR1 Capital Management LLC now owns 172,157 shares of the company’s stock worth $907,000 after acquiring an additional 148,514 shares during the period. 5AM Venture Management LLC purchased a new position in shares of Silence Therapeutics during the 2nd quarter worth $5,228,676. GAMMA Investing LLC boosted its stake in shares of Silence Therapeutics by 18.1% during the 2nd quarter. GAMMA Investing LLC now owns 11,063 shares of the company’s stock worth $121,000 after acquiring an additional 1,698 shares during the last quarter. SG Americas Securities LLC grew its position in shares of Silence Therapeutics by 11.8% during the 1st quarter. SG Americas Securities LLC now owns 286,698 shares of the company’s stock valued at $1,511,000 after acquiring an additional 30,358 shares during the period. Finally, Seven Fleet Capital Management LP grew its position in shares of Silence Therapeutics by 6.2% during the 1st quarter. Seven Fleet Capital Management LP now owns 156,759 shares of the company’s stock valued at $826,000 after acquiring an additional 9,159 shares during the period. Hedge funds and other institutional investors own 98.73% of the company’s stock.

Silence Therapeutics Company Profile

Silence Therapeutics plc is a clinical-stage biotechnology company focused on developing medicines that use small interfering RNA (siRNA) to selectively reduce the production of disease-related proteins. Its approach is designed to intervene at the genetic messenger RNA stage, potentially providing targeted and durable effects for patients with serious diseases.

The company’s proprietary mRNAi GOLD platform supports the design and delivery of siRNA medicines, including compounds intended to target tissues such as the liver.